Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Can J Diabetes. 2021 Feb;45(1):39-46. doi: 10.1016/j.jcjd.2020.05.004. Epub 2020 May 17.
Advanced glycation end products, along with methylglyoxal (MGO) as their precursor, play a major role in increased complications of type 2 diabetes mellitus (T2DM). Taurine (2-aminoethanesulphonic acid), a conditionally essential amino acid, is found in most mammalian tissues. Taurine is known as an antiglycation compound. This study was designed to investigate the effects of taurine supplementation on metabolic profiles, pentosidine, MGO and soluble receptors for advanced glycation end products in patients with T2DM.
In this double-blind randomized controlled trial, 46 patients with T2DM were randomly allocated into taurine and placebo groups. Participants received either 3,000 mg/day taurine or placebo for 8 weeks. Metabolic profiles, pentosidine, MGO and soluble receptors for advanced glycation end products levels were assessed after 12 h of fasting at baseline and completion of the clinical trial. Independent t test, paired t test, Pearson correlation and analysis of covariance were used for analysis.
The mean serum levels of fasting blood sugar (p=0.01), glycated hemoglobin (p=0.04), insulin (p=0.03), homeostasis model assessment-insulin resistance (p=0.004), total cholesterol (p=0.01) and low-density lipoprotein cholesterol (p=0.03) significantly were reduced in the taurine group at completion compared with the placebo group. In addition, after completion of the study, pentosidine (p=0.004) and MGO (p=0.006) were significantly reduced in the taurine group compared with the placebo group.
The results of this trial show that taurine supplementation may decrease diabetes complications through improving glycemic control and advanced glycation end products.
晚期糖基化终产物及其前体甲基乙二醛（MGO）在 2 型糖尿病（T2DM）并发症的增加中起主要作用。牛磺酸（2-氨基乙磺酸）是一种条件必需氨基酸，存在于大多数哺乳动物组织中。牛磺酸是一种抗糖基化化合物。本研究旨在探讨牛磺酸补充剂对 T2DM 患者代谢谱、戊糖素、MGO 和晚期糖基化终产物可溶性受体的影响。
在这项双盲随机对照试验中，将 46 例 T2DM 患者随机分为牛磺酸组和安慰剂组。参与者每天接受 3000mg 牛磺酸或安慰剂治疗 8 周。在基线和临床试验结束时禁食 12 小时后评估代谢谱、戊糖素、MGO 和晚期糖基化终产物可溶性受体水平。采用独立 t 检验、配对 t 检验、Pearson 相关分析和协方差分析进行分析。
与安慰剂组相比，牛磺酸组在完成治疗时空腹血糖（p=0.01）、糖化血红蛋白（p=0.04）、胰岛素（p=0.03）、稳态模型评估-胰岛素抵抗（p=0.004）、总胆固醇（p=0.01）和低密度脂蛋白胆固醇（p=0.03）的血清水平显著降低。此外，研究完成后，牛磺酸组的戊糖素（p=0.004）和 MGO（p=0.006）水平明显低于安慰剂组。
本试验结果表明，牛磺酸补充可能通过改善血糖控制和晚期糖基化终产物来减少糖尿病并发症。
